Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
Argus Health
Medtronic
Mallinckrodt
Merck
Teva
Farmers Insurance
Federal Trade Commission

Generated: May 21, 2018

DrugPatentWatch Database Preview

EPZICOM Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Epzicom, and when can generic versions of Epzicom launch?

Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has ninety-one patent family members in forty-eight countries.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Drug patent expirations by year for EPZICOM
Synonyms for EPZICOM
(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(+/-)-Abacavir
(+/-)-cis-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9-purinyl]-1-cyclopent-2-enyl]methanol
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol
[(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
[(1S,4R)-4-[2-azanyl-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
136470-78-5
136470-78-5 (Succinate)
1592U89
188062-50-2
2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-
2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)-
470A785
A807079
AB01566826_01
abacavir
Abacavir (INN)
Abacavir [INN:BAN]
Abacavir [INN]
Abacavir sulfate
AC-1299
AC1L9AXG
ACT03218
AK163479
AKOS024464970
AM015240
BC214924
BDBM50366816
Bio-0001
C-18039
C07624
CC-23613
CHEBI:421707
CHEMBL1380
CJ-31308
CS-1354
D07057
D0A4IJ
DB01048
DR001043
EN300-258000
Epitope ID:137341
FT-0631153
HE058172
HY-17423
J-700136
KS-00000XJM
MCGSCOLBFJQGHM-SCZZXKLOSA-N
MFCD00903850
MLS006010117
MolPort-006-069-118
NCGC00164560-01
NCGC00164560-02
NSC742406
NU000340
SC-16996
SC-20023
SCHEMBL38632
SMR004701251
ST24045890
UNII-WR2TIP26VS
W-5205
WR2TIP26VS
Ziagen
Ziagen (TM)(*Succinate salt*)
Ziagen (TN)
ZINC2015928

US Patents and Regulatory Information for EPZICOM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for EPZICOM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EPZICOM
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 600 mg/300 mg ➤ Subscribe 2007-09-27

or, see our see our flat-rate plans

Supplementary Protection Certificates for EPZICOM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/1999 Austria ➤ Try a Free Trial PRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628
C/GB99/032 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ABACAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE INCLUDING ABACAVIR SULPHATE; REGISTERED: CH CH 55048 001 19990628; CH CH 55049 002 19990628; UK EU/1/99/112/001 19990708; UK EU/1/99/112/002 19990708
99C0033 Belgium ➤ Try a Free Trial PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
0817637/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Teva
Accenture
Baxter
McKesson
Johnson and Johnson
Chinese Patent Office
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.